KROS
Price
$17.08
Change
+$0.16 (+0.95%)
Updated
Dec 20, 04:59 PM (EDT)
66 days until earnings call
MEOBF
Price
$1.73
Change
+$0.70 (+67.96%)
Updated
Dec 19 closing price
59 days until earnings call
Ad is loading...

KROS vs MEOBF

Header iconKROS vs MEOBF Comparison
Open Charts KROS vs MEOBFBanner chart's image
Keros Therapeutics
Price$17.08
Change+$0.16 (+0.95%)
Volume$9.43K
CapitalizationN/A
Mesoblast
Price$1.73
Change+$0.70 (+67.96%)
Volume$1M
CapitalizationN/A
KROS vs MEOBF Comparison Chart
Loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KROS vs. MEOBF commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MEOBF is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (KROS: $17.03 vs. MEOBF: $1.73)
Brand notoriety: KROS and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 150% vs. MEOBF: 2310%
Market capitalization -- KROS: $689.84M vs. MEOBF: $1.71B
KROS [@Biotechnology] is valued at $689.84M. MEOBF’s [@Biotechnology] market capitalization is $1.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, MEOBF is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish while MEOBF’s TA Score has 5 bullish TA indicator(s).

  • KROS’s TA Score: 5 bullish, 5 bearish.
  • MEOBF’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, MEOBF is a better buy in the short-term than KROS.

Price Growth

KROS (@Biotechnology) experienced а -9.56% price change this week, while MEOBF (@Biotechnology) price change was +67.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

KROS is expected to report earnings on Feb 27, 2025.

MEOBF is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($1.71B) has a higher market cap than KROS($690M). MEOBF YTD gains are higher at: 937.792 vs. KROS (-57.168). MEOBF has higher annual earnings (EBITDA): -62.82M vs. KROS (-185.94M). KROS has more cash in the bank: 531M vs. MEOBF (62.6M). KROS has less debt than MEOBF: KROS (19.3M) vs MEOBF (119M). MEOBF has higher revenues than KROS: MEOBF (5.9M) vs KROS (651K).
KROSMEOBFKROS / MEOBF
Capitalization690M1.71B40%
EBITDA-185.94M-62.82M296%
Gain YTD-57.168937.792-6%
P/E RatioN/AN/A-
Revenue651K5.9M11%
Total Cash531M62.6M848%
Total Debt19.3M119M16%
FUNDAMENTALS RATINGS
MEOBF: Fundamental Ratings
MEOBF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
82
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
58
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KROSMEOBF
RSI
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
56%
Momentum
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
60%
MACD
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
54%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
83%
N/A
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 4 days ago
61%
View a ticker or compare two or three
Ad is loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MBIRX50.820.88
+1.76%
Morgan Stanley Insight IR
TWSIX128.621.27
+1.00%
American Century Select I
BUIEX55.050.53
+0.97%
Buffalo Blue Chip Growth Instl Cl
PRGEX18.360.14
+0.77%
Pioneer Global Sustainable Equity R
MRJIX9.750.07
+0.72%
Morgan Stanley Multi-Asset Real Return I

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INZY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.65%
INZY - KROS
43%
Loosely correlated
+6.41%
AXON - KROS
43%
Loosely correlated
+2.60%
XENE - KROS
41%
Loosely correlated
-0.69%
TFFP - KROS
40%
Loosely correlated
N/A
RAPT - KROS
39%
Loosely correlated
+2.18%
More

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
-1.87%
COGT - MEOBF
39%
Loosely correlated
+0.51%
MESO - MEOBF
26%
Poorly correlated
-12.71%
KROS - MEOBF
26%
Poorly correlated
+0.65%
More